{"id":249960,"date":"2023-05-10T00:00:00","date_gmt":"2023-05-10T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0165-biopharma-major-depressive-disorder-dsm-v-epidemiology\/"},"modified":"2026-03-31T10:33:49","modified_gmt":"2026-03-31T10:33:49","slug":"epidcg0165-biopharma-major-depressive-disorder-dsm-v-epidemiology-epidemiology-major-depressive-disorder-dsm-v","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0165-biopharma-major-depressive-disorder-dsm-v-epidemiology-epidemiology-major-depressive-disorder-dsm-v\/","title":{"rendered":"Major Depressive Disorder (DSM-V) &#8211; Epidemiology &#8211; Epidemiology &#8211; Major Depressive Disorder (DSM V) &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>) (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders\">DSM<\/abbr>-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report the prevalence of <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\">DSM-<\/abbr>V) for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\">DSM-<\/abbr>V) forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\">DSM-<\/abbr>V), how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\">DSM-<\/abbr>V), how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\">DSM-<\/abbr>V) over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.<\/p>\n<p>Clarivate Epidemiology forecasts the following <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\">DSM-<\/abbr>V) patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total lifetime prevalent cases.<\/li>\n<li>Total 12-month prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249960","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-psychiatry","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249960\/revisions"}],"predecessor-version":[{"id":281622,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249960\/revisions\/281622"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}